Watch a KOL discuss the clinical data for OJJAARA in patients who have MF with anemia

Homepage image

START WITH A TREATMENT APPROVED FOR MF WITH ANEMIA

The first & only FDA-approved treatment indicated specifically for patients who have myelofibrosis (MF) with anemia.1,2

Bar graph icon

HEAD-TO-HEAD CLINICAL TRIALS

OJJAARA was assessed in two phase 3 clinical trials in JAKi-naïve and JAKi-experienced patients.

SEE THE DATA

Pill bottle icon

ONE PILL, ONCE DAILY

Learn more about recommended dosing information for OJJAARA.

SEE DOSAGE AND ADMINISTRATION

More videos icon

OJJAARA PEER DISCUSSIONS

Check out our video library to watch experts discuss OJJAARA.

SEE PEER VIDEOS

SAFETY PROFILE

Well-characterized safety profile assessed in JAKi-naïve and JAKi-experienced patients.

SEE OJJAARA SAFETY PROFILE

FDA=US Food and Drug Administration; JAKi=Janus kinase inhibitor.

References

  1. OJJAARA (momelotinib). Prescribing Information. GSK; 2023.
  2. Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7. doi:10.1186/s13045-021-01157-4